Navitoclax Plus Ruxolitinib for Untreated MF: Data From TRANSFORM-1

Andrew Kuykendall, MD, reviews data from TRANSFORM-1 on navitoclax plus ruxolitinib for untreated myelofibrosis, highlighting consistent response rates, no significant symptom improvement with the combination, and challenges managing thrombocytopenia caused by navitoclax, despite its activity and potential as a second-line treatment option.

EP: 1.How JAK Inhibitors Have Shaped the Landscape of MF

EP: 2.Pelabresib Plus Ruxolitinib for JAK Inhibitor-Naïve Patients: Data From MANIFEST and MANIFEST-2

Now Viewing

EP: 3.Navitoclax Plus Ruxolitinib for Untreated MF: Data From TRANSFORM-1

EP: 4.Navtemadlin Plus Ruxolitinib for Patients With MF who had Suboptimal Responses to Ruxolitinib

EP: 5.Selinexor Plus Ruxolitinib in JAK Inhibitor-Naïve Patients: Updated Results From XPORT-MF-034

EP: 6.Luspatercept With or Without Ruxolitinib for the Treatment of Anemia in Patients With MF: Data From ACE-536-MF-001

EP: 7.Future Directions in Combination Therapies for Myelofibrosis

EP: 8.Key Efficacy and Safety Takeaways From Recent Data on JAK Inhibitors for MF

EP: 9.The FREEDOM-2 Trial: Efficacy and Safety of Fedratinib in Patients With MF Previously Treated With Ruxolitinib

EP: 10.Selection and Sequencing of JAK Inhibitors for Patients With MF

EP: 11.Individualizing Therapy Goals for Patients With Myelofibrosis

EP: 12.Emerging Treatments for Myelofibrosis

Related Videos

Related Content

Advertisement

November 15th 2024

FDA Approves Revumenib for R/R Acute Leukemia With a KMT2A Translocation

March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

November 14th 2024

FDA Approves Nilotinib Tablets Without Mealtime Restrictions for CML

November 30th 2023

Lunning and Jacobson Dissect the Role of CAR T-Cell Therapy in Follicular Lymphoma

November 13th 2024

Real-World Experience With CAR T Varies From Trials in DLBCL

November 13th 2024

Retrospective Data Show Pacritinib Improves TSS in Transfusion-Dependent Myelofibrosis

Related Content

Advertisement

November 15th 2024

FDA Approves Revumenib for R/R Acute Leukemia With a KMT2A Translocation

March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

November 14th 2024

FDA Approves Nilotinib Tablets Without Mealtime Restrictions for CML

November 30th 2023

Lunning and Jacobson Dissect the Role of CAR T-Cell Therapy in Follicular Lymphoma

November 13th 2024

Real-World Experience With CAR T Varies From Trials in DLBCL

November 13th 2024

Retrospective Data Show Pacritinib Improves TSS in Transfusion-Dependent Myelofibrosis